Table 4.

Cytokine and immune modulatory molecule upregulation in mouse myeloma TEM following RV and BTZ combination treatment

SampleIFN-β, no. + MNC/×200 (SD)IFN-γ, no. + MNC/×200 (SD)MHC1, no. + MNC/×200 (SD)TAP1, no. + MNC/×200 (SD)TLR3, no. + MNC/×200 (SD)NF-κB, no. + MNC/×200 (SD)
Tumor-free control spleen 12.3 (4.4) 2.0 (0.7) 1.1 (0.4) 
Vehicle control myeloma spleen 7.1* (1.3) 15.2 (5.5) 19.5 (4.0) 4.1 (1.1) 13.5 (2.3) 12.2 (3.3) 
DV myeloma spleen 4.9 (2.0) 11.9 (5.9) 27.4 (7.9) 12.2 (4.7) 20.1 (6.3) 32.9 (6.0) 
BTZ myeloma spleen 15.0 (6.6) 23.2 (8.2) 29.0 (7.7) 5.0 (2.8) 34.3 (7.7) 33.9 (5.7) 
DV + BTZ myeloma spleen 18.1 (5.8) 28.9 (9.0) 25.2 (8.2) 15.9 (3.3) 27.9 (9.2) 28.9 (7.1) 
LV myeloma spleen (low productive infection) 14.1 (4.9) 18.8 (4.3) 111.9 (9.7) 48.9 (7.7) 109.4 (9.2) 69.5 (5.9) 
LV + BTZ myeloma spleen (productive infection) 83.2 (8.95) 76.1 (7.9) 218.15 (17.1) 91.3 (9.65) 116.0 (9.25) 76.35 (7.1) 
SampleIFN-β, no. + MNC/×200 (SD)IFN-γ, no. + MNC/×200 (SD)MHC1, no. + MNC/×200 (SD)TAP1, no. + MNC/×200 (SD)TLR3, no. + MNC/×200 (SD)NF-κB, no. + MNC/×200 (SD)
Tumor-free control spleen 12.3 (4.4) 2.0 (0.7) 1.1 (0.4) 
Vehicle control myeloma spleen 7.1* (1.3) 15.2 (5.5) 19.5 (4.0) 4.1 (1.1) 13.5 (2.3) 12.2 (3.3) 
DV myeloma spleen 4.9 (2.0) 11.9 (5.9) 27.4 (7.9) 12.2 (4.7) 20.1 (6.3) 32.9 (6.0) 
BTZ myeloma spleen 15.0 (6.6) 23.2 (8.2) 29.0 (7.7) 5.0 (2.8) 34.3 (7.7) 33.9 (5.7) 
DV + BTZ myeloma spleen 18.1 (5.8) 28.9 (9.0) 25.2 (8.2) 15.9 (3.3) 27.9 (9.2) 28.9 (7.1) 
LV myeloma spleen (low productive infection) 14.1 (4.9) 18.8 (4.3) 111.9 (9.7) 48.9 (7.7) 109.4 (9.2) 69.5 (5.9) 
LV + BTZ myeloma spleen (productive infection) 83.2 (8.95) 76.1 (7.9) 218.15 (17.1) 91.3 (9.65) 116.0 (9.25) 76.35 (7.1) 

SD, standard deviation; MNC, mononuclear cell.

*

All cell counts were done at the interface of myeloma cells and normal spleen and represent the number of positive cells at ×200. N = 2, mean of 10 fields (SD).

or Create an Account

Close Modal
Close Modal